|
15-11-2023 1:30 EST
| Nine-month interim report (Q3) 2023 |
|
9-11-2023 7:46 EST
| Release date of nine-month interim report (Q3) 2023 for ALK and audio cast |
|
11-10-2023 10:14 EDT
| Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children |
|
24-8-2023 1:30 EDT
| Six-month interim report (Q2) 2023 |
|
18-8-2023 6:45 EDT
| Release date of six-month interim report (Q2) 2023 for ALK and audio cast |
|
19-6-2023 2:41 EDT
| President & CEO Carsten Hellmann to step down end 2023. Peter Halling appointed as his successor |
|
8-6-2023 10:28 EDT
| Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s house dust mite tablet in young children |
|
9-5-2023 1:20 EDT
| Three-month interim report (Q1) 2023 |
|
1-5-2023 4:19 EDT
| Release date of three-month interim report (Q1) 2023 for ALK and audio cast |
|
17-4-2023 12:15 EDT
| ALK announces preliminary Q1 figures and confirms its full-year revenue and earnings outlook |
|
31-3-2023 11:30 EDT
| Grant of share-based long-term incentive instruments to members of the Board of Management and key employees |
|
23-3-2023 12:17 EDT
| Annual General Meeting in ALK-Abelló A/S held on 23 March 2023 |
|
2-3-2023 11:15 EST
| Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff |
|
27-2-2023 4:00 EST
| Annual General Meeting in ALK on 23 March 2023 |
|
10-2-2023 2:30 EST
| ALK appoints Claus Steensen Sølje as new Chief Financial Officer (CFO) |
|
8-2-2023 11:04 EST
| Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff |
|
3-2-2023 6:48 EST
| Regulatory filing for house dust mite allergy tablet accepted for review in China |
|
3-2-2023 6:09 EST
| Annual report 2022: ALK delivers sales growth of 13% with profits up 33% in 2022 |
|
27-1-2023 8:13 EST
| Release date of annual report 2022 for ALK and audio cast |
